Filing Analysis
Regulation FD Disclosure
Filed Mar 26, 2026
LOW
Gain Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. The information was furnished via a press release as part of a routine Item 2.02 filing.
Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The announcement was made on March 26, 2026.
- The report includes a business update in addition to financial metrics.
- The filing was signed by Gene Mack, Chief Executive Officer.
Regulation FD Disclosure
Filed Mar 18, 2026
MEDIUM
Gain Therapeutics announced positive clinical and biomarker data from its Phase 1b study of GT-02287 in Parkinson's Disease at the AD/PD 2026 conference. The data demonstrated substantial biomarker reductions and stable clinical scores over 150 days, alongside the introduction of a new IND-ready preclinical candidate.
Key Facts
- 16 out of 19 participants who completed Part 1 of the Phase 1b study elected to continue into the 9-month extension (Part 2).
- A Data Monitoring Committee (DMC) meeting on March 5, 2026, recommended the study continue without changes.
- Participants with elevated baseline GluSph levels saw substantial decreases in the biomarker after 90 days of treatment.
- MDS-UPDRS scores remained stable over 150 days of dosing as of March 10, 2026.
- A 6.7-point difference in MDS-UPDRS Part II and III scores was observed between high and low baseline GluSph groups at Day 150.
- The company announced GT-04686 as a new lead chemical series ready for IND-enabling studies.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.